Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Cancer
Interventions
BIOLOGICAL

IMC-1121B

"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"

BIOLOGICAL

1121B

"Cohort 2~8mg/kg I.V., once every other week for 4 weeks"

BIOLOGICAL

1121B

"Cohort 3~10 mg/kg I.V., once every other week for 4 weeks"

BIOLOGICAL

1121B

"Cohort 4~15 mg/kg I.V., once every 3 weeks for 6 weeks"

BIOLOGICAL

1121B

"Cohort 5~20 mg/kg I.V., once every 3 weeks for 6 weeks"

Trial Locations (3)

19111

ImClone Investigational Site, Philadelphia

27710

ImClone Investigational Site, Durham

46202-5112

ImClone Investigational Site, Indianapolis

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00786383 - Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy | Biotech Hunter | Biotech Hunter